by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Greater white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) are seen with transactive response DNA-binding protein 43 (TDP-43) pathology in frontotemporal lobar degeneration (FTLD-TDP). WMH associations with TDP-43 pathology...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Medicare’s Annual Wellness Visit (AWV) is a logical opportunity for early detection of cognitive impairment, but recent data for uptake and cognitive assessments during it are lacking. METHODS We surveyed Medicare beneficiaries of a...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most common neurodegenerative disease, characterized by damage to cortical circuits. However, the mechanisms underlying AD-associated changes in long-range circuits remain poorly understood. METHODS In this...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Novel fluid biomarkers for tracking neurodegeneration specific to Alzheimer’s disease (AD) are greatly needed. METHODS Using two independent well-characterized cohorts (n = 881 in total), we investigated the group differences in plasma...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract Extracellular vesicles (EVs) have emerged as novel blood-based biomarkers for various pathologies. The development of methods to enrich cell-specific EVs from biofluids has enabled us to monitor difficult-to-access organs, such as the brain, in real time...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION The plasma proteome’s mediating or moderating roles in the association between poor cardiovascular health (CVH) and brain white matter (WM) microstructural integrity are largely unknown. METHODS Data from 3953 UK Biobank participants were...
